目前对肺癌患者预后评价仍然依据临床分期，但即使相同临床分期的患者也会存在生存状况的差别，至今尚无有效预测肺癌患者预后的分子细胞遗传学标志。在前期工作中我们利用aCGH技术针对肺鳞状细胞癌高危（＜2年内死亡）和低危（＞5年生存）病例肿瘤组织分析结果显示，41个染色体片段可以将高、低危患者区分开来，并且以3p21.31、4q35.1的缺失以及5p13.2、14q32.33、19p13.11的扩增改变尤为显著，并从中筛选出这五个片段所涵盖的13个基因。本课题将在此基础上采用遗传学改变分辨精确度更高的Affymetrix SNP 6.0芯片技术，在独立大样本中对肺鳞癌组织进行全基因组拷贝数及Array-CGH所不能提示的杂合性缺失等进行分析，并重点对前期结果进行验证，试图筛选出一组有鉴别意义的扩增（或缺失）基因作为评估肺鳞癌预后的分子标志，为后续基因相关功能研究、临床预警预后和指导治疗提供依据。

Nowadays the clinical outcome of patients with lung cancer is mainly predicted according to clinical stage. However the prognosis can be different among patients with the same stage. So far, there are no molecular cytogenetic markers that can effectively predict patients' outcome. In our previous study, we compared molecular cytogenetic differences between high-risk (died in 2 years after operation) and low-risk (survived over 5 years after operation) patients with squamous cell lung cancer (SCC) using array-comparative genomic hybridization (array-CGH) analysis. 41 chromosomal fragments as a whole were identified to effectively separate high-risk group and low-risk group. Among the fragments, loss of 3p21.31 and 4q35.1 and gains of 5p13.2, 14q32.33 and 19p13.11 were more frequently detected including 13 genes. Based on these results, we decide to apply Affymetrix SNP 6.0 array analysis to further investigate genomic copy number variations (CNV) and loss of heterozygosity (LOH) in an independent sample group and emphasize on identifying key genes on 3p21.31, 4q35.1, 5p13.2, 14q32.33 and 19p13.11. In this project, we aim to select some genes/fragments as molecular cytogenetic markers, of which gain or loss can predict patients' outcome, in order to guide SCC clinical treatment.